Biotech

Kane Biotech announces update on private placement

Kane Biotech announces extension of private placement

Not for distribution to US news services or broadcast in the United States WINNIPEG, Manitoba, April 29, 2022 (GLOBE NEWSWIRE) – Kane Biotech Inc. (TSX-V: KNE) (the “Company” or “Kane Biotech”) today announced that it has extended the completion of its previously announced non-offering. private placement brokerage (the “Offer”) within 30 days until May 29, …

Kane Biotech announces extension of private placement Read More »

Nautilus Biotechnology (NAUT) versus competitive financial analysis

Healing biotechnology (OTCMKTS: CUBT) and agilon health (NYSE: AGL) analysis

Curative biotechnology (OTCMKTS: CUBT – Get Rating) and agilon Health (NYSE: AGL – Get Rating) are both medical companies, but what is the top title? We will compare the two companies based on the strength of analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership, and risk. Institutional and privileged property 96.2% of agilon health shares …

Healing biotechnology (OTCMKTS: CUBT) and agilon health (NYSE: AGL) analysis Read More »

Nautilus Biotechnology (NAUT) versus competitive financial analysis

Zacks: Analysts expect Nautilus Biotechnology, Inc. (NASDAQ: NAUT) to post – $ 0.17 EPS

Analysts expect Nautilus Biotechnology, Inc. (NASDAQ: NAUT – Get Rating) to post earnings per share (EPS) ($ 0.17) for the current quarter, according to Zacks. Zero analysts issued Nautilus Biotechnology earnings estimates, with the lowest EPS estimate coming in at ($ 0.18) and the highest estimate coming in at ($ 0.15). Nautilus Biotechnology reported earnings …

Zacks: Analysts expect Nautilus Biotechnology, Inc. (NASDAQ: NAUT) to post – $ 0.17 EPS Read More »

Nautilus Biotechnology (NAUT) versus competitive financial analysis

Financial Review of Healing Biotechnology (OTCMKTS: CUBT) and Agilon Health (NYSE: AGL).

Healing biotechnology (OTCMKTS: CUBT – Get Rating) and agilon Health (NYSE: AGL – Get Rating) are both medical companies, but what is the best investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends. Evaluation and earnings This table compares the gross …

Financial Review of Healing Biotechnology (OTCMKTS: CUBT) and Agilon Health (NYSE: AGL). Read More »

SM-164 market will see huge growth by 2029: Yeasen Biotech Co., Ltd., Target Molecule Corp., Shanghai yuanye Bio-Technology Co., Ltd, MedChemExpress (MCE), BioVision, Inc., Biorbyt Ltd ., APExBIO Technology LLC, Absinthe

SM-164 market will see huge growth by 2029: Yeasen Biotech Co., Ltd., Target Molecule Corp., Shanghai yuanye Bio-Technology Co., Ltd, MedChemExpress (MCE), BioVision, Inc., Biorbyt Ltd ., APExBIO Technology LLC, Absinthe

New Jersey, USA, Accuracy reports has published new research in Global SM-164 covering the micro level of analysis by competitors and key business segments (2022-2029). The Global SM-164 explores a comprehensive study on various segments such as opportunity, size, development, innovation, sales and overall growth of the major players. The research is conducted on primary …

SM-164 market will see huge growth by 2029: Yeasen Biotech Co., Ltd., Target Molecule Corp., Shanghai yuanye Bio-Technology Co., Ltd, MedChemExpress (MCE), BioVision, Inc., Biorbyt Ltd ., APExBIO Technology LLC, Absinthe Read More »

Brickell Biotech announces the sale of sofpironium bromide to Botanix Pharmaceuticals

Brickell Biotech will report first quarter 2022 financial results and provide a business update on May 12, 2022

Brickell Biotech BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) – Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform the lives of patients developing innovative products and differentiated prescription drugs for the treatment of autoimmune, inflammatory and other debilitating diseases, announced today that it will present its first …

Brickell Biotech will report first quarter 2022 financial results and provide a business update on May 12, 2022 Read More »

7 cheap biotech stocks to buy now

InvestorPlace – Stock market news, stock advice and trading tips This article covers seven low-cost biotech stocks for investors with high risk tolerance. Bio immunity (IBRX): boasts a broad pipeline covering multiple chronic conditions. Select Biosciences (SELB): Clinical stage biotechnology with trucks loaded with cash to take its new immune tolerance platform over the finish …

7 cheap biotech stocks to buy now Read More »

AbbVie, AstraZeneca See the value in what Cugene, Proteros have to offer

AbbVie, AstraZeneca See the value in what Cugene, Proteros have to offer

It is common for smaller biotech companies with interesting technology platforms to partner with larger biopharmaceutical companies. Two such deals were announced today: Cugene and AbbVie on autoimmune diseases and cancer, and Proteros and AstraZeneca on epigenetic anticancer drugs. Read on for more details. AbbVie and Cugene collaborate on autoimmune diseases and cancer Based in …

AbbVie, AstraZeneca See the value in what Cugene, Proteros have to offer Read More »

Matica Biotechnology and G-CON Manufacturing complete the project

Matica Biotechnology and G-CON Manufacturing complete the project

May 4, 2022 CDMO for Cell and Gene Therapy completed its new 45,000 square foot facility which included 8 prefabricated cleanroom PODs from G-CON Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial manufacturing of cell and gene therapies, has announced the opening of its new 45,000 square foot …

Matica Biotechnology and G-CON Manufacturing complete the project Read More »